✦ LIBER ✦

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)

✍ Scribed by Koizumi, Wasaburo; Kim, Yeul Hong; Fujii, Masashi; Kim, Hoon Kyo; Imamura, Hiroshi; Lee, Kyung Hee; Hara, Takuo; Chung, Hyun Cheol; Satoh, Taroh; Cho, Jae Yong; Hosaka, Hisashi; Tsuji, Akihito; Takagane, Akinori; Inokuchi, Mikito; Tanabe, Kazuaki; Okuno, Tatsuya; Ogura, Mariko; Yoshida, Kazuhiro; Takeuchi, Masahiro; Nakajima, Toshifusa

Book ID: 121570572
Publisher: Springer-Verlag
Year: 2013
Tongue: English
Weight: 812 KB
Volume: 140
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-013-1563-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized phase III study of adjuvant

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

✍ Aristotelis Bamias; M. Karina; P. Papakostas; I. Kostopoulos; M. Bobos; G. Vourl 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 640 KB

A randomized phase 2 study of docetaxel

A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy

✍ Hei-Cheul Jeung; Sun Young Rha; Chong Kun Im; Sang Joon Shin; Joong Bae Ahn; Woo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

Impact of treatment with bevacizumab bey

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

✍ Masayuki Takeda, Isamu Okamoto, Takeharu Yamanaka, Kazuhiko Nakagawa, Yoichi Nak 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 149 KB

Contribution of chemotherapy (CMT) to th

Contribution of chemotherapy (CMT) to the survival (S) of patients (P) with advanced gastric cancer (AGC). A retrospective comparative study of patients who received and those who refused treatment (Tx)

✍ Tsavaris, N.; Kosmidis, P.; Kosmas, C.; Katsikas, M.; Bacoyiannis, Ch.; Mylonaki 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 219 KB

A phase III randomized trial of BAY 12-9

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

✍ H. Hirte; I.B. Vergote; J.R. Jeffrey; R.N. Grimshaw; S. Coppieters; B. Schwartz; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

A Phase II, randomized, double-blind stu

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)

✍ Cognetti, F.; Bagnato, A.; Colombo, N.; Savarese, A.; Scambia, G.; Sehouli, J.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 310 KB